Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Google Scholar citation report
Citations : 2091
Journal of Gastrointestinal & Digestive System received 2091 citations as per Google Scholar report
Journal of Gastrointestinal & Digestive System peer review process verified at publons
Indexed In
- Index Copernicus
- Google Scholar
- Sherpa Romeo
- Open J Gate
- Genamics JournalSeek
- China National Knowledge Infrastructure (CNKI)
- Electronic Journals Library
- RefSeek
- Hamdard University
- EBSCO A-Z
- OCLC- WorldCat
- SWB online catalog
- Virtual Library of Biology (vifabio)
- Publons
- Geneva Foundation for Medical Education and Research
- Euro Pub
- ICMJE
Useful Links
Recommended Journals
Related Subjects
Share This Page
Can use Golgi protein 73(GP73), as a serum biomarker for early surveillance of hepatocellular carcinoma in the first stage and chronic liver diseases in Saudi Arabia patients
14th International Conference on Clinical Gastroenterology and Hepatology
Randa Mohamed MA Farag, Dujana AlAyobi, Hye-Joo Kwon, Khalid A Alsaleh, Afaf EL-Ansary and Emad A Dawoud
Princess Nourah Bint Abdulrahman University, Kingdom Saudi ArabiaKing Saud University, Kingdom Saudi ArabiaEL-Azher University and Tawam Hospital, UAE
Posters & Accepted Abstracts: J Gastrointest Dig Syst
Abstract
This study was performed to quantify the expression of Golgi protein-73 (GP73) in healthy controls and in patients with liver disease, and to evaluate the correlations between GP73 and other serum markers in different liver diseases. Study the sensitivity and specificity of Golgi Glypican-73 (GP37) as new biomarker useful in early prediction for Hepatocellular Carcinoma in hepatitis viruses (HBV, HCV) and in chronic liver Cirrhosis; Also in chronic liver diseases. Serum GP73 was measured in 478 healthy controls and 296 patients with different types of liver disease. Quantitative hepatitis B virus (HBV) DNA was determined in two chronic hepatitis B (CHB) groups. Other serum liver fibrosis markers were measured in the liver fibrosis group and α-fetoprotein (AFP) was measured in hepatocellular carcinoma (HCC) group. The correlations between GP73 and these markers were evaluated. The GP73 value in hepatitis B-e-antigen (HBeAg)-positive CHB group, HBeAg-negative CHB group, liver fibrosis group and HCC group was significantly higher (p<0.001) than that in healthy controls. GP73 showed significant correlation with other markers in the liver fibrosis group and with AFP in the HCC group. Compared with healthy controls, GP73 in patients with liver disease was significantly increased. With the progression of liver disease, GP73 showed a significantly increasing trend. These results suggest that GP73 might be used as a serum marker for the diagnosis of liver diseases and for monitoring disease progressionBiography
E-mail: randa792006@gmail.com
